Literature DB >> 2318249

Interleukin 4 receptors on normal human B lymphocytes: characterization and regulation.

C E Zuber1, J P Galizzi, A Vallé, N Harada, M Howard, J Banchereau.   

Abstract

Human interleukin 4 (IL 4) up-regulates the expression of CD23 on both resting and "in vivo" activated B cells but induces proliferation and/or differentiation only on "in vitro" activated B lymphocytes. Resting B cells express 360 high-affinity IL 4 receptors (R) per cell (Kd = 25-75 pM). Activation of resting B cells with anti-IgM antibody or Staphylococcus aureus Cowan I (SAC) results in a two-to-threefold increase of IL 4R number without alteration of IL 4R affinity for IL 4. Flow cytometric analysis of biotinylated IL 4 binding shows that IL 4R expression is up-regulated on virtually all anti-IgM-stimulated B cells, but only on a subpopulation of larger cells among SAC-activated B lymphocytes. Culturing cells for 40 h with optimal concentrations of IL 4 does not significantly affect IL 4R levels on resting and anti-IgM-preactivated B lymphocytes but triples IL 4R levels on SAC-preactivated B cells. Removal of IL 4 from cell cultures results in a two-to-fourfold increase of IL 4R levels 2 h later, suggesting an increase in IL 4R turnover. Resting and activated B cells degrade 125I-labeled IL 4 at 37 degrees C. Sodium dodecyl sulfate-polyacrylamide gel electrophoretic analysis of IL 4 binding molecules on resting, "in vivo" activated and anti-IgM-activated B cells reveals the same three species of 130, 80-75, 70-65 kDa. Thus, IL 4 displays its different biological activities on resting and activated B cells through IL 4R of the same affinity, gross biochemical structure and ability to mediate IL 4 degradation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318249     DOI: 10.1002/eji.1830200314

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Effects of interleukins on the proliferation and survival of chronic lymphocytic leukaemia cells.

Authors:  M H Gilleece; C M Heyworth; N G Testa; T M Dexter
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

2.  Recombinant interferon-gamma inhibits the expression of IL-4 receptors on human lymphocytes.

Authors:  K A Byron; G A Varigos; A M Wootton
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

3.  Interleukin-4 may contribute to the abundant T-cell reaction and paucity of neoplastic B cells in T-cell-rich B-cell lymphomas.

Authors:  W R Macon; J B Cousar; J A Waldron; S M Hsu
Journal:  Am J Pathol       Date:  1992-11       Impact factor: 4.307

4.  Oligoclonal activation of CD4+ T lymphocytes in posterior uveitis.

Authors:  E J Feron; V L Calder; S L Lightman
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

5.  Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections--a phase I dose toxicity trial.

Authors:  M H Gilleece; J H Scarffe; A Ghosh; C M Heyworth; E Bonnem; N Testa; P Stern; T M Dexter
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.